EGFR and non-small cell lung carcinoma: The patient died one month later with evidence of new brain metastases.<h4>Conclusion</h4>This case highlights primary resistance to the third-generation EGFR-TKI almonertinib in a patient with NSCLC harboring a germ-line EGFR V831H mutation.